William Ashe
Pediatric Pulmonology · Charlotte, NCNPI 1891801262
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 309 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations. Among pediatric pulmonology clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 309 payments — averaging $19.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$1K
- Regeneron Healthcare Solutions, Inc.$1K
- AstraZeneca$843
- GSK$372
- Aytu Biopharma, Inc.$340
- Covis Pharma GmbH$270
- plus $2K from 29 others
Across 3 payments — averaging $2419.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$7K
What the payments were for
- Food & beverage$6,178100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 49 | $1,310 |
| Regeneron Healthcare Solutions, Inc. | 48 | $1,079 |
| AstraZeneca | 51 | $843 |
| GSK | 21 | $372 |
| Aytu Biopharma, Inc. | 21 | $340 |
| Covis Pharma GmbH | 21 | $270 |
| Novartis | 17 | $261 |
| Pfizer | 13 | $241 |
| Kaleo, Inc. | 8 | $161 |
| Integra Lifesciences Corporation | 1 | $150 |
| ARS Pharmaceuticals Operations, Inc. | 6 | $146 |
| CSL Behring | 6 | $119 |
| Aerin Medical Inc. | 1 | $119 |
| Gilead | 8 | $108 |
| Alk-abello, Inc | 4 | $90 |
| Genentech USA, Inc. | 5 | $79 |
| Optinose US, Inc. | 4 | $67 |
| Merck | 3 | $53 |
| Amgen | 2 | $34 |
| Philips North America LLC | 2 | $32 |
| Grifols USA, LLC | 2 | $31 |
| Hikma Pharmaceuticals USA | 2 | $30 |
| Biocryst US Sales Co., LLC | 1 | $28 |
| Dermavant Sciences, Inc. | 1 | $26 |
| AbbVie | 2 | $26 |
| Siemens Medical Solutions USA, Inc. | 1 | $21 |
| Ironshore Pharmaceuticals Inc. | 1 | $20 |
| USWM, LLC | 1 | $19 |
| Circassia Inc. | 1 | $19 |
| Chiesi USA, Inc. | 1 | $16 |
| Mylan Specialty L.p. | 1 | $16 |
| Phadia US Inc. | 1 | $15 |
| Aimmune Therapeutics, Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Neos Therapeutics, LP | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$240
- Acclarent Aera$150
- Inspira Air$150
- RELIEVA SPINPLUS NAV$150
- TruDi Probe$150
- VIVAER STYLUS$119
- RHINAER STYLUS$119
How this compares
$6,178 in reported general payments places this provider in the 90th percentile of 37 pediatric pulmonology providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cetirizine Hcl | 14 | $106 |
Paid to pharmacies, not to this prescriber.
Other pediatric pulmonology in Charlotte
- Ashley ChadhaCharlotte$5K
- Hugh BlackCharlotte$3K
- Marc ChesterCharlotte$1K
- Maxine EikaniCharlotte$722
- Rosemary MegalaaCharlotte$579
- Jeffrey ClearyCharlotte$455
- Dennis SchellhaseCharlotte$230
- Shean AujlaCharlotte$208
- Robert GardnerCharlotte$201
- Robert TillmanCharlotte$115
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.